Altimmune presents results of a phase 2 mri-based body composition sub-study at 60th annual meeting of the european association for the study of diabetes

Lean loss ratio of only 21.9%, representing class-leading preservation of lean mass maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures visceral adipose tissue (vat), a risk factor for cardiovascular disease, reduced by 25.6% at week 48 gaithersburg, md., sept. 10, 2024 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today presented data from its phase 2, mri-based body composition sub-study of pemvidutide in subjects with overweight and obesity at the 60th annual meeting of the european association for the study of diabetes (easd) in madrid, spain.
ALT Ratings Summary
ALT Quant Ranking